About Us

Our Story

Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases. Leveraging our AI-based integrated computational platform, LANCE, we have identified seven novel therapeutic candidates to date across thirteen indications in areas of unmet medical need. Our lead product candidate, BT-11, is a small molecule targeting Lanthionine Synthetase C-Like 2 (LANCL2), a pathway designed to limit its impact to the gastrointestinal tract. The Company is evaluating BT-11 in a Phase 2 trial for mild to moderate ulcerative colitis (UC) study in the U.S. Europe, and Russia and expects to initiate a Phase 2 trial of BT-11 for the treatment of moderate to severe Crohn’s disease (CD) in the first half of 2021.

The Company’s mission is to create safer and more effective treatments that address the therapeutic gap in the current treatment paradigm for autoimmune disease.

Management Team

Josep Bassaganya-Riera

Josep Bassaganya-Riera, Ph.D.

Chairman, President and CEO

Read More
Raquel Hontecillas

Raquel Hontecillas, Ph.D.

Chief Scientific Officer

Read More
Jyoti Chauhan

Jyoti Chauhan, M.S., RAC (US)

Executive Director, Global Clinical Operations & Regulatory Compliance

Read More
Andrew Leber

Andrew Leber, Ph.D.

Scientific Director

Read More
Jennifer Collette

Jennifer Collette, CPA

Financial Director & Controller

Read More
simon lichtiger

Simon Lichtiger, M.D.

Medical Director

Read More

Board of Directors

Josep Bassaganya-Riera, Ph.D.

Chairman, President and CEO

Read More

Chris Garabedian

Xontogeny, Perceptive Advisors

Read More

Konstantin Poukalov

Managing Director – Strategy, Perceptive Advisors

Read More

Roderick Wong, M.D., MBA

Managing Partner, RTW Investments

Read More

Clinical Advisory Board

Maria T. Abreu, M.D.

Read More

Jean-Frederic Colombel, M.D.

Read More

Fabio Cominelli, M.D., Ph.D.

Read More

Asher Kornbluth, M.D.

Read More

William J. Sandborn, M.D.

Read More

Francisco Sylvester, M.D.

Read More

Investors